Reported about 8 hours ago
The biotech sector is currently facing challenges due to the recent freeze and subsequent lifting of federal funding for key research programs. Analysts highlight that the uncertainty surrounding funding, particularly in light of potential regulatory changes with Robert F. Kennedy Jr.'s confirmation as Secretary of HHS, adds complexity to the industry's landscape. Despite these challenges, some companies like Enliven Therapeutics and Protagonist are identified as promising investments.
Source: YAHOO